PDGFRA copy number changes (ratio >2) were observed in 52.6% (30 out of 57) of glioma patients: 18 displayed ratios <5 and were considered representative of aneuploidy/aneusomy and 12 (21.1%) harboured ratios ⩾5 and were considered amplified (Table 1). Here, PDGFRA is linked to central nervous system cancer.